Study Submission Changes

Bellberry’s mission is to protect the welfare of research participants and to improve the quality, efficiency and effectiveness of research.

Whenever possible, we are always striving to make improvements to streamline the HREC process. In November 2020, several important changes to the Bellberry submission process came into effect.

The transition period for these changes has now ended. From 1 Jan any documents submitted that do not comply with these changes will be returned with guidance on how to proceed. If you have any queries regarding these changes, please contact the Bellberry office at bellberry@bellberry.com.au

Key Changes

Master and site specific PICF and other participant facing documents

New applications: The first submitting/lead site must consult PICF submission pathways to determine how the master study documentation will be submitted. There are now three submission pathways:

  • Option 1 for single centre submission;
  • Option 2 is a flexible submission pathway (which is the same as currently in place);
  • Option 3 for where the initial submitting/lead site takes submission responsibility.

A question has been added to the application form asking the Principal Investigator to confirm which PICF pathway has been chosen for the submission. Only one pathway may be selected per study for review by a Bellberry HREC. Each additional site will need to align with the study’s nominated pathway, chosen by the first submitting/lead site.

Sites are no longer required to submit tracked and clean site-specific PICFs and other site-specific participant facing documentation to Bellberry. This change allows sites with research governance offices (or other formal institutional arrangements for reviewing site-specific documentation) to go ahead without the need for further HREC review. Sites that do not have a formal institutional arrangement will be responsible for developing a local procedure for document management.

The PICF submission pathway will determine what documentation is required from each site. Major site-based changes (e.g. radiation, pregnancy, reimbursement) to the PICF/participant facing documentation may be written in the master document as placeholders, or by the completion of Site-specific clauses. The content will be reviewed by the HREC in the format determined by the PICF pathway. Minor administrative changes will be the responsibility of the site and do not need to be submitted to Bellberry. These include adding the site name, Principal Investigator details, amending footers, formatting, and other typographical errors.

For current/ongoing studies: Most studies will already be consistent with one of the PICF pathways. If a site has submitted a site-specific PICF/document to Bellberry, the HREC will have already approved the site-specific content and listed it on an approval letter. If the master document is updated, the site can continue to imbed previously approved clauses into the new site-specific PICF/document without the need for further HREC review. If the site wishes to change a clause, the site must submit an amendment using the Site-specific clauses template.

Initial applications and reviews

Each site is responsible for submitting an initial application. The first submitting/lead site is responsible for submitting all core study documents. Additional sites will not need to submit any study documentation that has been submitted by the first submitting/lead site, irrespective of when the additional site joins. However, additional sites are responsible for submitting documents that have not been submitted by the first submitting/lead site (e.g. documents pertaining to the additional site: CV, social media plan, advertising, etc.). Please refer to Submission requirements for further information.

Additional site submissions will be considered by the Chair/reviewers as the first submitting/lead site enters cycle comments, post-HREC review.  When the first submitting/ lead site is ready for approval, any additional sites that have fulfilled the HREC’s requirements will be included on the first submitting/lead site approval letter.

Additional sites approved post initial approval

When an additional site is approved after the initial study’s approval, Bellberry administration will upload all previous approval letters to eProtocol page 7 of the additional site’s application. The additional site is responsible for checking that the approved documents match the documents on file. If the site has any documents that do not match those approved (e.g. they have a more recent version of the protocol), the site is responsible for contacting the sponsor to determine which of the approved sites will be responsible for submitting an amendment.

Please refer to HREC process flowchart for further information.

Amendments and safety reporting

If an amendment or safety report in a multi-centre study relates to core study documentation (such as the protocol, master PICF or investigator brochure, DSUR, ASR), the submission will be reviewed on behalf of all Bellberry approved sites. In the event the submission does not apply to all of these sites, the submitting site must provide an explanation. Please refer to Amendment pathways flowchart for further information.

Serious breaches

Protocol deviations and violations do not need to be reported to Bellberry HREC. The PVR form has been updated to reflect the NHRMC’s serious breach questions. Sites may complete these questions, or upload Serious breaches report form – sponsor or Serious breaches report form – third party, as applicable.

Please note, the acknowledgement letter will code the item as ‘PVR’; this is system-generated and cannot be altered.

Progress reports

Minor changes have been made to the progress report form to incorporate the need for submissions to include an update on any conflict of interest changes for the research team, and for a comment on compliance with any: governance approvals; submission of amendments; safety reporting; annual progress reporting; notification to the HREC of regulatory audits; appropriate use of data; caveats placed on the approval; statutory and licensing obligations. See Progress reports (eProtocol questions).

Version control and document naming conventions

For clarity, Bellberry requests files to contain the title, version and date of the document. Please refer to Version control and document naming conventions for further information.

HREC Indemnities

Bellberry accepts both electronic and hard copy HREC Only indemnities. If an indemnity is to be sent via an electronic platform such as DocuSign or AdobeSign, please do not complete any fields for the Bellberry signatory.

Please send any electronic HREC Only Indemnities to bellberry@bellberry.com.au. If your processes require it to be sent to an individual, please also copy to bellberry@bellberry.com.au.

Bellberry does not require the submission of Standard Indemnities. Researchers and Sponsors can find information on Bellberry’s requirements for HREC Only Indemnities in Insurance and indemnities

Submission requirements

As a reminder, earlier this year, Bellberry removed the requirement to submit the following documents for which the institution is responsible:

  • Insurance certificates
  • Standard indemnities
  • Site approval forms*
  • Protocol signature pages
  • Professional indemnities

These are still required to be in place, and available at the site.

*Site approval forms, in this context, refer to the procedure of form put in place by the Institution or Organisation conducting the research. The Bellberry site approval form has been retired.

A list of submission requirements is available under Bellberry Applications Submission requirements checklist.

Sponsor submissions

Sponsor representatives are able to help build the applications in eProtocol. See registration requirements under Submission requirements and responsibilities

Summary of Changes document (including all related documentation and staff contacts)

Share this article:

Other articles

A blog for the latest news and articles related to the ethical review of human research from Bellberry Limited.

View all articles
Apr 30, 2026

Impact Report 2025

We’re proud to share Bellberry’s 2025 Impact Report - our first report bringing together key insights, data and achievements from the past…

Read More
Feb 17, 2026

2026 Podcast Season: More About NAMs

When a potential new medicine is tested on humans for the first time it is a milestone. It is thoroughly tested for…

Read More
Dec 23, 2025

Bellberry Newsletter – Summer 2025

Welcome to our newsletter for summer 2025. The Bell contains a roundup of the activities Bellberry has been involved with in the…

Read More
Nov 12, 2025

2025/26 Bellberry-Viertel Fellow Announced

Last month at the Australian Academy of Health and Medical Sciences Gala Dinner in Canberra our new Bellberry-Viertel Fellow was announced! Congratulations…

Read More
Sep 30, 2025

National Statement Updates 2025

The National Statement on Ethical Conduct in Human Research is the principal reference for research involving humans in Australia and is the…

Read More
Sep 30, 2025

Operations Update 28

In the September issue of our Operations Update please find articles on: New Bellberry office address New eProtocol registrations contact email Bellberry…

Read More
Sep 30, 2025

Bellberry User Satisfaction Survey

As Australia’s largest provider of Human Research Ethics Committee services, Bellberry places great value on understanding the experience our users have of…

Read More
Sep 30, 2025

International Research Administrators Day

Today, September 25, we celebrate International Research Administrators Day! This globally recognised day honours the contribution of Research Administrators in supporting and…

Read More
Jun 12, 2025

NAMs workshop summary report released

We are pleased to release the summary report from the Bellberry & ASCEPT New Approach Methodologies (NAMs) Introductory Workshop, held in Melbourne,…

Read More
May 21, 2025

Clinical Trial Activity Report (CTAR) 2024

Report highlights international confidence in Australian clinical trials Global investment in Australian clinical trials is strong, with two thirds of Australian clinical…

Read More
May 21, 2025

Podcast Episode 12: From Lab to Life

Worldwide there is growing focus on using NAMs (Non-Animal Models also known as Novel Approach Methods) in the development of therapeutics. In…

Read More
Mar 11, 2025

Participant Engagement at Scientific Meetings

Bellberry is delighted to share details of our grant program to support participant engagement at scientific meetings. Conference organisers can apply to…

Read More
Feb 14, 2025

Podcast Episode 11: From Lab To Life

In 2004 Bellberry was founded as a paradigm breaker. We are an institutionally independent not-for-profit company that offers Human Research Ethics Committee…

Read More
Nov 29, 2024

Bellberry wins National Award for Health!

We are delighted to share that Bellberry won the National Telstra Best of Business award in the Championing Health category in Melbourne…

Read More
Nov 26, 2024

Telstra Best of Business Award – National Finalist!

Bellberry CEO Kylie Sproston and Communications Manager Alison Rogers, are on their way to Melbourne today in preparation for their final pitch…

Read More